![CarThera secures €5.7m](https://ala.associates/wp-content/uploads/2016/10/Frederic-Sottilini.png)
![CarThera secures €5.7m](https://ala.associates/wp-content/uploads/2016/10/Frederic-Sottilini.png)
![Domain Therapeutics, UdeM, IRICoR and McGill University extend agreement on GPCR biosensor technology](https://ala.associates/wp-content/uploads/2016/11/Pascal-Neuville-2016-e1478702603628-992x675.jpg)
Domain Therapeutics, UdeM, IRICoR and McGill University extend agreement on GPCR biosensor technology
![BioCellChallenge reports very promising results from its first intravenous assay](https://ala.associates/wp-content/uploads/2016/10/Unknown-1080x675.jpeg)
BioCellChallenge reports very promising results from its first intravenous assay
![More than 20 smart tech firms selected to pitch for funding at the INPHO® Venture Summit](https://ala.associates/wp-content/uploads/2016/10/inpho-venture-summit-backdrop-1080x458.jpg)
More than 20 smart tech firms selected to pitch for funding at the INPHO® Venture Summit
![Adebiotech et le Pôle IAR, partenaires pour décloisonner les biotechnologies](https://ala.associates/wp-content/uploads/2016/09/Logo-Adebiotech-IAR.png)
Adebiotech et le Pôle IAR, partenaires pour décloisonner les biotechnologies
Transfert de technologie : Startsquare propose aux entrepreneurs 25 technologies innovantes du CNES
![Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial](https://ala.associates/wp-content/uploads/2016/09/photo_francois_conquet-500x675.jpg)
Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial
![Novasep and Triclinic Labs enter a strategic alliance for solid-state chemistry services](https://ala.associates/wp-content/uploads/2016/09/Thierry-Van-Nieuvenhowe_007.jpg)
Novasep and Triclinic Labs enter a strategic alliance for solid-state chemistry services
![BrainVectis raises €1 million to develop its gene therapy for Huntington’s and Alzheimer’s diseases](https://ala.associates/wp-content/uploads/2016/09/Nathalie_Cartier-Lacave.png)
BrainVectis raises €1 million to develop its gene therapy for Huntington’s and Alzheimer’s diseases
![Alizé Pharma III presents preclinical results from its I-HBD1 program at the Annual Meeting of the American Society for Bone and Mineral Research](https://ala.associates/wp-content/uploads/2016/09/DSC00880-1080x675.jpg)